Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-05-29
2007-05-29
Parkin, J S (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S238000
Reexamination Certificate
active
08286189
ABSTRACT:
An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using β-propiolactone, a non-ionic detergent, particularly n-octyl-α-D-glucopyranoside and n-octyl-β-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
REFERENCES:
patent: 4591505 (1986-05-01), Prince
patent: 4664912 (1987-05-01), Wiktor et al.
patent: 4732683 (1988-03-01), Georgiades et al.
patent: 5071758 (1991-12-01), Stott et al.
patent: 5223254 (1993-06-01), Paradiso et al.
patent: 9100104 (1991-01-01), None
patent: WO 93/21310 (1993-10-01), None
Hall: Prospects for a respiratory Syncytial virus vaccine: Science: vol. 265: pp. 1393-1394, Sep. 1994.
Hildreth, et al. : Lack of detectable enhanced pulmonary . . . : Vaccine: vol. 11, Iss. 6: pp. 615-618, 1993.
Toms: Respiratory syncytial virus . . . : Archives of Dis. child. : 72: pp. 1-5, 1995.
Hall, C. B., “Prospects for a respiratory syncytial virus vaccine”, Science 265:1393-1394, 1994.
Tristam, D. A., et al., “Respiratory syncytial virus vaccines: Can we improve on nature?”, Pediatr. Annals 22:715-718, 1993.
Toms, G. L., “Respiratory syncytial virus-how soon can we have a vaccine?”, Arch. Dis. Childhood 72:1-3, 1995.
Murphy, B. R., et al., “An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines”, Vir. Res. 32:13-36, 1994.
Salkind, A. R. and N. J. Roberts, Jr., “Recent observations regarding the pathogenesis of recurrent respiratory syncytial virus infections: implications for vaccine development”, Vaccine 10(8):519-523, 1992.
Glezen, W.P., Paredes, A. Allison, J.E., Taber, L.H. and Frank, A.L. (1981). J. Pediatr. 98, 708-715.
Chanock, R.M., Parrot, R.H., Coonors, M., Collins, P.L. and Murphy, B.R. (1992) Pediatrics 90, 137-142.
Martin, A. J., Gardiner, P.S. and McQuillin, J. (1978). Lancet ii, 1035-1038.
Robbins, A., and Freeman, P. (1988) Sci. Am. 259, 126-133.
Glezen, W.P., Taber, L.H., Frank, A.L. and Kasel, J.A. (1986) Am. J. Dis. Child. 140, 143-146.
Katz, S.L. New vaccine development establishing priorities. vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
Wertz, G.W., Sullender, W.M. (1992) Biotech. 20, 151-176.
McIntosh, K. and Chanock, R.M. (1990) in Fields Virology (Fields, B.M., and Knipe, D.M. eds.) pp. 1045-1075, Raven Press, Ltd., New York.
Walsh, E.E., Hall, C.B., Briselli, M., Brandiss, M.W. and Schlesinger, J.J. (1987) J. Infect. Dis. 155, 1198-1204.
Walsh, E.E., Hruska, J. (1983) J. Virol. 47, 171-177.
Levine, S., Kleiber-France, R., and Paradiso, P.R. (1987) J. Gen. Virol. 69, 2521-2524.
Anderson, L.J., Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, K. (1985) J. Infect. Dis. 151, 626-633.
Johnson, P.R., Olmsted, R.A., Prince, G.A., Murphy, B.R., Alling, D.W., Walsh, E.E. and Collins, P.L. (1987) J. Virol. 61 (10), 3163-3166.
Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) Am. J. Epidemiol. 89 (4), 435-448.
Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
Kapikian, A.Z., Mitchell, R.H., Chanock, R.M., Shvedoff, R.A. and Stewart, C.E. (1969) Am. J. Epidemiol. 89 (4), 405-421.
Kim, H.W., Arrobio, J.O., Plyles, G., Brandt, C.D., Camargo, E., Chanock, R.M. and Parrott, R.H. (1971) Pediatrics 48, 745-755.
Wright, P.F., Belshe, R.B., Kim, H.W., Van Voris, L.P. and Chanock, R.M. (1982) Infect. Immun. 37 (1), 397-400.
Wright, P.F., Chinozaki, T. and Fleet, W. (1976) J. Pediatr. 88, 931-936.
Belshe, R.B., Van Voris, L.P. and Mufson, M.A. (1982) J. Infect. Dis. 145, 311-319.
Murphy, BR., Prince, G.A., Walsh, E.E, Kim H.W., Parrott, R.H., Hemming V.G., Rodriguez, W.J., and Chanock. J. Clin. Microbiol. (1986), 24 (2), 197-202.
Connors, M., Collins, P.L., Firestone, C-Y., Sotnikov, A.V., Waitze, A., Davis, A.R., Hung, P.P., Chanock, R.M., Murphy, B. (1992) Vaccine, 10, 475-484.
Prince, G.A., Jenson, A.B., Hemming,, V. G., Murphy, B.R., Walsh, E.E., Horswood, R.L and Chanock, R.L. (1986 b) J. Virol. 57 (3), 721-728.
Piedra, P.A., Camussi, F. and Ogra, P.L. (1989) J. Gen. Virol. 70, 325-333.
Walsh, E.E., Hall, C.B., Briselli, M., Brandiss, M.W. and Schlessinger, J.J. (1987) J. Infect. Dis. 155 (6), 1198-1204.
Budowsky, E.I. and Zheleznova, N.V. (1991) Vaccine 9 (6), 319-325.
Budowsky, E.I., Friedman, E.A., Zheleznova, N.V. and Noskov, F.S. (1991) Vaccine 9 (6), 398-402.
Stephan, W., Dichtelmuller, H., Prince, A.M., Brotman, B. and Huima, T. J. Med. Virol. (1988), 26 (3), 227-232.
Barth, R., Gruschkau, H., Bijok, U., Hilfenhaus, J., Hinz, J. and Milcke, L. J. Biol. Stand. (1984), 12 (1), 29-46.
Collins et al. Vaccine 8(2): 164-168, 1990.
Preston et al. Journal of Infect. Disease 165(5): 819-825 1992.
Moiguino et al. J. of Virol. Methods 31: 161-170, 1991.
Downing et al. J. of Virol. Methods 32: 215-228, 1992.
Salkind, A.R., et al, Recent observations regarding the pathogenesis of recurrent respiratory syncytial virus infections: implications for vaccine development., RSV and Vaccine Development.
Murphy et al, Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses—Virus Research 11, (1988) pp. 1-15.
Kimman, T.G., et al—Immunity to human and bovine respiratory syncytial virus—Arch. Virol. (1990) pp. 1-25.
Wertz, G.W., Approaches to Immunization against Respiratory Syncytial Virus—(1992) Biotechnology 20: 151-176.
LaVia W.V. et al, Respiratory syncytial virus puzzle: Clinical features, pathophysiology, treatment, and prevention—J. of Pediatrics—Oct. 1992, vol. 121 No. 4, pp. 503-510.
Prince. G.A., et al, Quantitative Aspects of Passive Immunity to Respiratory Syncytial Virus Infection in Infant Cotton Rats,, (J. Virol. Sep. 1985, vol. 55, No. 3; pp. 517-520.
Walsh, E.E., et al, Immunization with Glyoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection; J. of Infect. Dis. vol. 155, No. 6, Jun. 1987; pp. 1198-1204.
Prince, G.A., Immunoprophylaxis and immunotherapy of respiratory Syncytial virus infection in the cotton rat; Virus Res, 3 (1985)pp. 193-206.
Crowe, J.E., et al—PNAS vol. 91, pp. 1386-1390, Feb. 1994.
Groothius, J.R., et al—New England J. of Medicine, Nov. 1993; Vo. 329; pp. 1524-1530.
Paradiso, P.R., et al, Pediatr. Infect. Dis. J., 1994, 13:792-8 vol. 13, No. 9, Sep. 1994.
Budowsky E.I. et al., 1993, Vaccine 11(3):343-348.
Salo R.J. et al., 1978, App. Env. Microbiol. 36:68-75.
Bissell M.J. et al., 1980, PNAS USA 77:2711-2715.
Coe, J.E. and Prince, G.A.—Immunology 1996, 88, pp. 323-330.
Ewasyshyn Mary Elizabeth
Klein Michel Henri
Sanhueza Sonia E.
Parkin J S
Sanofi Pasteur Limited
Sim & McBurney
Stewart Michael I.
LandOfFree
Inactivated respiratory syncytial viral vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inactivated respiratory syncytial viral vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inactivated respiratory syncytial viral vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3748616